Pacira reports preliminary total revenues for 2017

Pacira Pharmaceuticals Inc. reported preliminary unaudited total revenues and net product sales of its bupivacaine liposome injectable suspension for the fourth quarter and full year of 2017.

According to a company press release, preliminary net sales for the company’s bupivacaine liposome injectable suspension Exparel was $78.7 million for the fourth quarter of 2017 compared with $71.4 million for the year prior. Net sales for the full-year 2017 were $282.9 million vs. $265.8 million for the previous year.

For the fourth quarter of 2017, total revenues were $79.1 million compared with $72.9 million for the year prior. Total revenue for the full-year 2017 was $286.6 million compared with $276.4 million for the previous year.

“2017 was an exciting year marked by solid revenue growth and multiple major milestones that support our mission of improving patient care with Exparel, our opioid-free alternative for prolonged postsurgical pain control,” Dave Stack, chairman and CEO of Pacira Pharmaceuticals Inc., said in the press release “Our Phase 4 PILLAR study unequivocally demonstrated that Exparel is significantly better than bupivacaine at reducing or eliminating opioids while successfully managing postsurgical pain. Our regulatory activities to expand the Exparel label to include nerve block are advancing on track. We are also continuing to promote education and awareness around opioid-sparing strategies while building a robust network of partners who share in our commitment to reducing the role of the operating room as the gateway to opioid use and abuse.”

Reference: